Navigation Links
Immtech Announces Update on Business Operations
Date:3/12/2008

NEW YORK, March 12 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) announced today that Eric L. Sorkin, the Company's Chairman and Chief Executive Officer, and Cecilia Chan, Vice Chairman of Immtech, have volunteered to reduce their annual salary during fiscal year 2008.

Eric L. Sorkin, Immtech's Chairman and Chief Executive Officer stated, "We are advancing Immtech's new business plans and other global health related projects as well as furthering our new drug discovery programs. We are utilizing our core strengths, including our extensive experience in China, to achieve Immtech's successes in this year and the years to come."

The Company filed Form 8K with the United States Securities and Exchange Commission with updated information on the Company's operations. As detailed in the 8K, due to recognition of deferred revenue, the Company's stockholders' equity exceeds $6.0 million and the Company expects that it will continue to exceed that amount as of March 31, 2008.

About Immtech Pharmaceuticals, Inc.

Immtech is a pharmaceutical company focused on the development and commercialization of new drugs to treat infectious diseases. Immtech has a well defined, expanding library of compounds targeting Hepatitis C, drug- resistant Gram-positive bacteria, fungal infections and other serious diseases. It is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat a range of disorders. Immtech holds exclusive worldwide licenses to certain patents, patent applications and technology for products derived from its proprietary pharmaceutical platform. For additional information, please visit the Company's website at http://www.immtechpharma.com.

This press release contains "forward-looking statements" regarding Immtech Pharmaceuticals, Inc.'s business, including the future prospects for Pneumocystis pneumonia (PCP). Except for historical information, the matters discussed in this press release are "forward-looking statements" and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidates, including PCP; (vii) the success of Immtech's clinical trials; (viii) dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to contract with a third party to manufacture its drug candidates at a reasonable cost; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) potential exposure to significant product liability.

Additional risks are discussed in the Company's current filings with the Securities and Exchange Commission. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Immtech Investor Conference Call Scheduled for February 22, 2008
2. Immtech Investor Conference Call Scheduled for January 3, 2008, at 1 PM
3. Immtech Announces Pafuramidine (DB289) Program on Clinical Hold
4. Immtech Completes Malaria Prevention Trial
5. IOF announces Progress in Osteoporosis now available free online
6. Omnicell Announces Completion of Its Common Stock Repurchase Plan
7. Independence Blue Cross Announces Blue Distinction Centers for Complex and Rare Cancers(SM) in Philadelphia
8. SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results
9. Thermage, Inc. Announces Initial Shipments of Cellulite Product
10. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
11. NHP Announces Management Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions ... definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an ... an educational webinar, they will present the line of epMotion automated liquid handling ... easy you can automate everyday pipetting tasks. , Ideal for scientists and lab ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston ... east Texas, is launching a regional charity effort to provide publicity assistance and ... Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based ... area, is spearheading a regional charity campaign organized to provide support to Christina Upchurch ... of this year, Christina and her children returned from out of town to find ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the ... efforts with its product now available through Jet.com. , After 25 years of ... powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 15, 2017 AccuGenomics, Inc., a diagnostic company ... announced that the company has provided an AccuKit to ... Carolina at Chapel Hill and to Qura Therapeutics for ... and quantify HIV reservoir and viral expression in human ... HIV Cure Center is a joint initiative between the ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology: